Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Atopic Dermatitis: full-pipeline trial registry
55 of 151 indexed Atopic Dermatitis trials are currently recruiting.
Corpus placement: #76 of 28,707 conditions by registered trial count.
151 US clinical trials · 55 currently recruiting · #76 of 28,707 conditions by registered trial count
Atopic Dermatitis: 151 US clinical trials tracked, 55 recruiting.
Atopic Dermatitis is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 55 of them currently open to new participants. 47 are in Phase 3-4 (later-stage) and 66 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 10 of these trials.
Enrollment posture brief
Registry condition atopic-dermatitis
OPEN 55 | RECR 36% | LATE 47 | EARLY 66 | RANK #76 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Acquired Brain Injury (36% recruiting · 11 trials)
Atopic Dermatitis lists 55 open slots (36% of 151 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Atopic Dermatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Atopic Dermatitis recruits in line with its size-band peers.
55 of 151 indexed trials (36.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Atopic Dermatitis trials is spread across many organizations.
Pfizer accounts for 10 of 151 trials (6.6%). 80 distinct sponsors appear on at least one study for this condition label.
-
Typical Atopic Dermatitis enrolment sits around 137 participants.
Median target enrolment is 137 among the 151 trials that report a genuine target (sentinel values excluded). 65 of those (43%) plan for fewer than 100 participants.
-
Atopic Dermatitis research is mostly interventional.
122 interventional and 29 observational studies make up this index (80.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
151 total, page 1 of 4
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
NCT05635266
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
Incyte Corporation
NCT06627335
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Regeneron Pharmaceuticals
NCT03936335
Natural History and Genetics of Food Allergy and Related Conditions
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02504853
CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
CorEvitas
NCT06238765
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Sanofi
NCT07290803
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Galderma R&D
NCT06988605
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
Incyte Corporation
NCT06259669
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
University of California, San Diego
NCT05938478
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
AbbVie
NCT06461897
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
National Human Genome Research Institute (NHGRI)
NCT00605878
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
NCT06807281
Registry for Systemic Eczema Treatments
Johns Hopkins University
NCT06136767
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
Pfizer
NCT05721937
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics
NCT07003425
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Pfizer
NCT05995964
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04864886
Skin Microbial Ecology in Atopic Dermatitis
University of Rochester
NCT04170244
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Incyte Corporation
NCT06832618
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
NCT06947993
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Inmagene
NCT07037901
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Eli Lilly and Company
NCT07006792
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
University of Michigan
NCT06300697
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
University of Pittsburgh
NCT00177268
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Corvus Pharmaceuticals
NCT07441395
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Kymera Therapeutics
NCT07217015
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie
NCT06389136
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Bambusa Therapeutics
NCT06808477
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
LEO Pharma
NCT06311682
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Organon and
NCT07265479
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Hoffmann-La Roche
NCT06863961
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
UCB Biopharma SRL
NCT07277660
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Pfizer
NCT06899204
Cardamom and Topical Roseomonas in Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06096857
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Hoffmann-La Roche
NCT07223697
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Pfizer
NCT06564389
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
Boston Children's Hospital
NCT04455906
A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis)
Turn Therapeutics
NCT07355075
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Aclaris Therapeutics
NCT07011706
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Oneness Biotech Co.
NCT06397911
A Study Evaluating TRIV-509 in Atopic Dermatitis
Triveni Bio
NCT07167758
Sodium in the Skin and Atopic Dermatitis
University of California, San Francisco
NCT06998446
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06504160
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
NCT07220577
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
AbbVie
NCT06524635
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Icahn School of Medicine at Mount Sinai
NCT07242638
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Johann E Gudjonsson MD PhD
NCT06906497
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Brexogen
NCT06055361
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Northwestern University
NCT05042258
Dupixent and Narrowband UVB for Atopic Dermatitis
Psoriasis Treatment Center of Central New Jersey
NCT05285839
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 48 |
| Phase 3 | 28 |
| Phase 4 | 19 |
Top Sponsors
Named interventions
Most-linked intervention names on Atopic Dermatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Atopic Dermatitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Atopic Dermatitis page
151 registered trials, 55 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 55 Atopic Dermatitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Atopic Dermatitis trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atopic Dermatitis condition card totals 151 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.